Evidence map›Paper›PMID 42795607›Full record

ArticleMicroorganisms2026

Design and Evaluation of a Multi-Epitope Vaccine Targeting Conserved Envelope and NS5 Proteins of Usutu Virus Using Immunoinformatics.

Reem Alromaihi, Hajed Obaid Alharbi, Suleman Abdullah Almerdasi, Mawahib A Ahmed, Waad A Aljohani, Mona Alromaihi, Laila Alhussain, Alaa Karkashan, Riham Mohamad Rashad Mohamad, Khaled S Allemailem

Abstract read
In one paragraph

Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Reem AlromaihiDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.
Hajed Obaid AlharbiDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.ORCID 0000-0003-4566-2932
Suleman Abdullah AlmerdasiDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.ORCID 0000-0001-8330-7945
Mawahib A AhmedDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.ORCID 0009-0004-9550-7150
Waad A AljohaniDepartment of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.ORCID 0000-0002-8619-0081
Mona AlromaihiDepartment of Pediatrics, College of Medicine, Qassim University, Buraydah 51452, Saudi Arabia.
Laila AlhussainDepartment of Biology, College of Science, Qassim University, Buraydah 51452, Saudi Arabia.
Alaa KarkashanDepartment of Biological Sciences, College of Science, University of Jeddah, Jeddah 21959, Saudi Arabia.
Riham Mohamad Rashad MohamadDepartment of Laboratory and Blood Bank, Buraydah Central Hospital, Buraydah 52361, Saudi Arabia.
Khaled S AllemailemDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.ORCID 0000-0002-6486-9835

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Usutu virus is an emerging mosquito-borne flavivirus with an expanding geographic distribution and increasing public health relevance, yet no licensed vaccine is currently available. This study used an integrated reverse vaccinology strategy to identify conserved immunogenic regions from the Envelope protein and NS5 protein, and construct a multi-epitope vaccine. Following sequential computational screening, the retained T-cell and B-cell epitopes satisfied the predefined selection criteria, while selected T-cell epitopes achieved an estimated 96.41% global population coverage. The final vaccine consisted of 240 amino acids and incorporated an adjuvant together with peptide linkers. Computational characterization indicated favorable physicochemical features and a refined three-dimensional model with improved stereochemical characteristics. Receptor-binding analyses predicted favorable interactions with TLR2 and TLR4, producing weighted docking scores of -1326.1 and -1230.2, respectively. Molecular dynamics simulation further characterized the temporal behavior of the vaccine-TLR2 complex, while MM-GBSA analysis yielded an estimated binding energy of -74.78 kcal/mol. C-ImmSim predicted enhanced humoral and cellular immune-response patterns following repeated antigen administration, including increased simulated antibody levels and changes in immune-cell populations. All findings in this study are based on in silico analyses and represent computational predictions rather than experimentally confirmed results. Further experimental validation is required to verify the predicted properties, immunogenicity, and protective potential of the proposed vaccine candidate.

Indexed as

Envelope proteinmolecular dockingmolecular dynamicsNS5 proteinreverse vaccinologyUsutu virus

Identifiers

PMID42795607
PMCPMC13609697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.